ReviewDrugs & aging2007
Individualising therapy for older adults with diabetes mellitus.
Review in Drugs & aging, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Management of Type 2 Diabetes in Frail Older Adults.Drugs & aging · 2023Article
- The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study.Medicine · 2017Observational
- Managing diabetes in people with dementia: protocol for a realist review.Systematic reviews · 2016Article
- Review
- Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes.Journal of endocrinology, diabetes & obesity · 2014Article
- Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes.Diabetology & metabolic syndrome · 2014Article
- Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.Drugs & aging · 2012Review
- Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus--a cohort study.PloS one · 2012Article
- Frailty and safety: the example of diabetes.Drug safety · 2012Review
- Special considerations with insulin therapy in older adults with diabetes mellitus.Drugs & aging · 2011Review
- Do we need individualised prescribing quality assessment? The case of diabetes treatment.International journal of clinical pharmacy · 2011Article
- Development of CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project: rationale and methodology.Drugs & aging · 2009Review
- Antidiabetic oral treatment in older people: does frailty matter?Drugs & aging · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal when treating patients with diabetes mellitus is to achieve the maximum longevity consistent with an optimal quality of life. To achieve this goal, treatment is typically focused on management of hyperglycaemic symptoms and prevention of microvascular and macrovascular complications. While appropriate for most individuals, including many older adults with robust health, this focus is often too limited for older adults facing diminished life expectancy and co-existing medical illness, frailty and disability. Creating a treatment plan that optimises health and function, and reduces the risk for morbidity and mortality, requires individualised therapy that judiciously manages symptoms and multiple competing health risks while remaining consistent with the patient's or his/her caregiver's healthcare preferences. Physicians caring for older adults with diabetes must be adept at recognising conditions commonly associated with diabetes, including the interplay with co-morbid illness, and be able to assess the patient's health status and use this information to recommend a treatment plan that is consistent with the patient's personal goals for care. The majority of older adults with diabetes will benefit from management of cardiovascular risk, including intensive management of hypertension, lipids, use of aspirin (acetylsalicylic acid) and smoking cessation, and screening for common geriatric syndromes. For a significant minority of older adults with life expectancy of >or=10 years, it is reasonable to consider intensive management of hyperglycaemia (glycosylated haemoglobin [HbA1c] target<or=7%). For frail older adults with life expectancy of <or=5 years, strategies for reducing medical burden, improving function and moderate glucose control (HbA1c approximately 8%) is reasonable and sufficient to control hyperglycaemic symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.